| __timestamp | Amicus Therapeutics, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 1271353000 |
| Thursday, January 1, 2015 | 76943000 | 1620577000 |
| Friday, January 1, 2016 | 104793000 | 2052295000 |
| Sunday, January 1, 2017 | 149310000 | 2075142000 |
| Monday, January 1, 2018 | 270902000 | 2186100000 |
| Tuesday, January 1, 2019 | 286378000 | 3036600000 |
| Wednesday, January 1, 2020 | 308443000 | 2735000000 |
| Friday, January 1, 2021 | 272049000 | 2908100000 |
| Saturday, January 1, 2022 | 276677000 | 3592500000 |
| Sunday, January 1, 2023 | 152381000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
Regeneron, a leader in the field, has consistently outpaced Amicus in R&D spending, with an average annual expenditure nearly 13 times higher. This substantial investment has fueled Regeneron's growth, with a notable peak in 2023, where R&D expenses surged by 25% compared to the previous year.
Conversely, Amicus has shown a more modest yet steady increase in R&D spending, peaking in 2020. Despite a dip in 2023, Amicus's strategic focus on targeted therapies continues to drive its innovation pipeline.
These spending patterns highlight the diverse approaches within the biotech industry, where both giants and emerging players strive to lead in groundbreaking therapies.
R&D Insights: How Gilead Sciences, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
Analyzing R&D Budgets: Takeda Pharmaceutical Company Limited vs Amicus Therapeutics, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. vs ImmunityBio, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Amicus Therapeutics, Inc. and Travere Therapeutics, Inc.
Amicus Therapeutics, Inc. or Evotec SE: Who Invests More in Innovation?